DNA Biomed Solns Market Cap ($38.30 Million)
Market Cap & Net Worth: DNA Biomed Solns (DNA)
DNA Biomed Solns market cap. DNA Biomed Solns (TA:DNA) has a market capitalization of $38.30 Million (ILA14.29 Billion) as of October 31, 2026. Listed on the TA stock exchange, this Israel-based company holds position #22729 globally and #314 in its home market, demonstrating a 0.78% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying DNA Biomed Solns's stock price ILA116.00 by its total outstanding shares 123164100 (123.16 Million).
DNA Biomed Solns Market Cap History (2015–2026)
DNA Biomed Solns market cap history from 2015 to 2026. Data shows change from $369.69 Million to $38.30 Million (-21.09% CAGR). Check DNA stock price for real-time trading data and today's change.
DNA Biomed Solns Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how DNA Biomed Solns's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash efficiency ratio of DNA Biomed Solns for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
99.49x
DNA Biomed Solns's market cap is 99.49 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.38x
DNA Biomed Solns's market cap is 1.38 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $24.24 Million | $560.00K | -$23.54 Million | 43.28x | N/A |
| 2023 | $20.87 Million | $306.00K | -$1.18 Million | 68.20x | N/A |
| 2024 | $30.44 Million | $306.00K | $22.10 Million | 99.49x | 1.38x |
Competitor Companies of DNA by Market Capitalization
Companies near DNA Biomed Solns in the global market cap rankings as of October 31, 2026. See DNA Biomed Solns balance sheet quality to understand what proportion of total assets are financed by equity.
Key companies related to DNA Biomed Solns by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of DNA Biomed Solns (2015–2026)
Market capitalization of DNA Biomed Solns from 2015 to today. Between 2015 and today, DNA Biomed Solns's market cap moved from $369.69 Million to $ 38.30 Million, with a yearly change of -21.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA38.30 Million | +16.00% |
| 2025 | ILA33.02 Million | +8.46% |
| 2024 | ILA30.44 Million | +45.89% |
| 2023 | ILA20.87 Million | -13.90% |
| 2022 | ILA24.24 Million | -53.51% |
| 2021 | ILA52.14 Million | +112.52% |
| 2020 | ILA24.53 Million | +6.29% |
| 2019 | ILA23.08 Million | -91.37% |
| 2018 | ILA267.46 Million | -51.82% |
| 2017 | ILA555.13 Million | +28.65% |
| 2016 | ILA431.50 Million | +16.72% |
| 2015 | ILA369.69 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of DNA Biomed Solns was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.30 Million USD |
| MoneyControl | $38.30 Million USD |
| MarketWatch | $38.30 Million USD |
| marketcap.company | $38.30 Million USD |
| Reuters | $38.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About DNA Biomed Solns
Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physi… Read more